Rodney Gerard Rootsaert - Jun 1, 2025 Form 4 Insider Report for VOLITIONRX LTD (VNRX)

Role
Secretary
Signature
/s/ Rodney Gerard Rootsaert
Stock symbol
VNRX
Transactions as of
Jun 1, 2025
Transactions value $
-$3,223
Form type
4
Date filed
6/3/2025, 04:06 PM
Previous filing
May 5, 2025
Next filing
Jul 3, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Rootsaert Rodney Gerard Secretary 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON /s/ Rodney Gerard Rootsaert 2025-06-03 0001577894

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VNRX Common Stock Award $0 +10.2K +7.41% $0.00 148K Jun 1, 2025 Direct F1
transaction VNRX Common Stock Tax liability -$3.22K -6.41K -4.34% $0.50 141K Jun 1, 2025 Direct F2
holding VNRX Common Stock 1.01M Jun 1, 2025 By Concord International, Inc. F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 1, 2025, the reporting person was awarded 10,190 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 3,397 units, 3,397 units, and 3,396 units on each of June 1, 2025, July 1, 2025 and August 1, 2025, respectively, are also subject to further time-based vesting in a single installment on August 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.
F2 Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 15,258 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.
F3 The shares of common stock are held directly by Concord International, Inc. The reporting person is a controlling director of Concord International, Inc. and shares voting and dispositive control over the shares of common stock held by Concord International, Inc.